It’s Not Oral.It’s Not IV.It’s Enbumyst.
Not absorbed like an oral. Not administered like an IV — by design.
Enbumyst is the first FDA approved nasal spray formulation of bumetanide for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including nephrotic syndrome in adults.
Enbumyst is contraindicated in patients with anuria, are in hepatic coma, and have a history of hypersensitivity to bumetanide.
Please see Important Safety Information below.
Why Enbumyst?
- Demonstrated similar effects on diuresis, natriuresis, and urinary potassium excretion as oral bumetanide tablets and IV injection.1
- Single-use nasal spray that is designed for ease of use in any setting
- Intranasal route avoids reliance on GI absorption
- Same device platform found in certain FDA-approved emergency intranasal therapies
- Intended to support outpatient stabilization and care continuity
Indication & Important Safety Information
INDICATION
ENBUMYST is indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including nephrotic syndrome in adults.
IMPORTANT SAFETY INFORMATION
ENBUMYST is contraindicated in patients with anuria, are in hepatic coma, and have a history of hypersensitivity to bumetanide.
ENBUMYST is a diuretic that may cause fluid, electrolyte, and metabolic abnormalities. Excessive fluid loss can lead to dehydration, decreased blood volume, and increased risk of blood clots. Abnormalities may include changes in blood electrolytes, nitrogen, glucose, and uric acid. The chance of getting these abnormalities is higher in people who are elderly, use higher doses, or who do not get enough electrolytes by mouth.
If increasing azotemia and oliguria occur during treatment of severe progressive renal disease, discontinue bumetanide.
Although unlikely at the recommended doses, the potential for ototoxicity must be considered a risk of intravenous therapy, at high doses, repeated frequently in the face of renal excretory function impairment.
Avoid use in patients with significant nasal mucosal or structural abnormalities, such as acute episodes of rhinitis or congestion due to any cause.
Advise lactating women treated with ENBUMYST to monitor their infants for excessive urine output, dehydration, and lethargy.
Most common adverse reactions are hypovolemia, headache, muscle cramps, dizziness, hypotension, nausea and encephalopathy (in patients with pre-existing liver disease).
These are not all of the possible side effects of ENBUMYST. To report suspected adverse reactions, contact Corstasis Therapeutics at 1-877-300-5339 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see the full Prescribing Information for ENBUMYST.
References:
1 Enbumyst Prescribing Information. Corstasis Therapeutics, Inc. 09/2025